Important Safety Information
Full Prescribing Information
Patient Package Insert
Instructions For Use
It may be good to know that Tyvaso® is the #1 prescribed inhalable prostacyclin treatment for pulmonary arterial hypertension (PAH) and can improve the ability to exercise in people who also take bosentan (an endothelin receptor antagonist (ETRA)) or sildenafil (a phosphodiesterase-5 (PDE-5) inhibitor). You breathe it in 4 times a day, using a lightweight, portable inhalation system.
Ask your doctor if you are not sure if this applies to you.
The most common side effects of Tyvaso include:
Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of Tyvaso. For more information, ask your doctor or specialty pharmacist.
You may also contact United Therapeutics Corporation at 1-877-864-8437 or via e-mail at drugsafety@unither.com to report suspected side effects, or contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Tyvaso was studied in one of the largest clinical trials to date of add-on therapy in patients with PAH. The goal of the trial, called TRIUMPH I, was to see if Tyvaso improved exercise ability in patients already taking an oral PAH medicine. Exercise ability was assessed using a test that measures the distance walked in 6 minutes (6-minute walk distance (6MWD)). Doctors commonly measure 6MWD to assess the ability of patients with PAH to do exercise.
For more information, download the Patient Package Insert. Also Available in Spanish
* Ability to exercise assessed using measures 6-minute walk distance (6MWD)
TRIUMPH=TReprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension
Tyvaso is a prescription medicine used in adults to treat pulmonary arterial hypertension (PAH) (WHO Group 1), which is high blood pressure in the arteries of your lungs. Tyvaso can improve exercise ability in people who also take bosentan (an endothelin receptor antagonist) or sildenafil (a phosphodiesterase-5 inhibitor). The effects decrease over 4 hours; treatment timing can be adjusted for planned activities.
Studies establishing effectiveness included predominately patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%).
Other medical conditions and medicines may affect your use of Tyvaso by increasing the risk of side effects or decreasing effectiveness. It is important to tell your doctor about your medical conditions and any medicines you may be taking, including:
The most common side effects of Tyvaso are coughing, headache, throat irritation and pain, nausea, reddening of the face and neck (flushing), and fainting or loss of consciousness. These are not all the possible side effects of Tyvaso. Tell your doctor about any side effects that bother you or do not go away. Your doctor may be able to help you manage the side effects.
For more information about Tyvaso, please see the Full Prescribing Information, Patient Package Insert, and the Tyvaso Inhalation System Instructions for Use Manual. Questions? Call the Customer Service Line at 1-877-UNITHER (1-877-864-8437).
| 1. | McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55:1915-22. |
Click "CONTINUE" to proceed or "RETURN" to return to TYVASO.com
The content of the linked site is the sole responsibility of the site provider. United Therapeutics Corporation does not control or endorse this third-party site.
Click "CONTINUE" to proceed or "RETURN" to return to TYVASO.com
The information contained in this section of the site is clinical in nature and specifically created for healthcare professionals. If you are not a U.S. healthcare professional, please click "RETURN" to return to the consumer section of the site.
Yes, I am a U.S. healthcare professional and would like to continue.